Erythema Migrans-like COVID Vaccine Arm: A Literature Review.
COVID Vaccine Arm (CVA)
COVID-19
Cominarty® Pfizer/BioNTech’s (BNT162b2) vaccine
Erythema migrans-like
Spikevax® Moderna (mRNA-1273) vaccine
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
received:
04
12
2021
revised:
24
01
2022
accepted:
30
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
COVID Vaccine Arm (CVA) is an adverse drug reaction from mRNA vaccine for SARS-CoV-2. CVA is characterized by erythema and edema on the vaccination site (usually deltoid area) that appears from 5 to 10 days after vaccination and is sometimes associated with itching or pain. The exact etiology of CVA is still unclear, but delayed hypersensitivity against an excipient seems to play an essential role in the pathogenesis of the disease. This work performs a systematic literature review on CVA using three different databases containing articles published until 10 November 2021. The literature review includes eight papers reporting single cases or case series of CVA. Moreover, it also addresses, other cutaneous reactions following COVID 19 vaccinations as well as possible differential diagnosis. CVA migrans-like erythema is characterized by a ring-shaped rash in the injection area, which appears some days after the injection and disappears in about 10 days. This reaction may appear more rapidly in subsequent doses.
Identifiants
pubmed: 35160249
pii: jcm11030797
doi: 10.3390/jcm11030797
pmc: PMC8836892
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
JAMA Dermatol. 2021 Jun 1;157(6):716-720
pubmed: 33978670
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e867-e868
pubmed: 34416053
N Engl J Med. 2021 Apr 1;384(13):1273-1277
pubmed: 33657292
J Allergy Clin Immunol. 1984 Oct;74(4 Pt 1):494-8
pubmed: 6491095
J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e730-e732
pubmed: 34242422
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):e26-e28
pubmed: 34547138
Vis J Emerg Med. 2021 Oct;25:101108
pubmed: 34423142
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):172-180
pubmed: 34661927
Cureus. 2021 Apr 13;13(4):e14453
pubmed: 33996313
Dermatol Ther. 2021 Sep;34(5):e15063
pubmed: 34250736
Dermatol Ther. 2020 Jul;33(4):e13681
pubmed: 32447798
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e423-e425
pubmed: 33783017
World J Clin Cases. 2021 Jul 16;9(20):5744-5751
pubmed: 34307634
Bull Cancer. 2021 Jun;108(6):668-669
pubmed: 33972089
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):957-961
pubmed: 33677050
Arch Dermatol Res. 2022 Jan;314(1):1-15
pubmed: 33559733
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211024431
pubmed: 34120504
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
Pediatr Dermatol. 2018 Sep;35(5):e262-e264
pubmed: 29998475
Medicina (Kaunas). 2021 Aug 16;57(8):
pubmed: 34441034
Viruses. 2020 Mar 27;12(4):
pubmed: 32230900
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1423-1437
pubmed: 33388478
Dermatol Clin. 2021 Oct;39(4):653-673
pubmed: 34556254
Acta Med Indones. 2021 Jul;53(3):326-330
pubmed: 34611073
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e425-e427
pubmed: 33783873
JAAD Case Rep. 2021 Apr;10:92-95
pubmed: 33748377